Takeda prepping to take over EU production of stem cell therapy from 2021BioPharma-Reporter.comFollowing its acceptance for review by the European Medicines Agency (EMA), Takeda and TiGenix announced this week Swissmedic has accepted for review the fil… Continue reading
STAT |
Bluebird Bio’s gene therapy for blood disorders yields some impressive results ― but also raises questions
STAT he field of gene therapy is making significant strides towards the day when a one-time treatment ― inserting a healthy gene into patients ― could cure a host of inherited, often fatal diseases. But it’s been a rocky road 1. And new clinical data … Drug Product in Patients with Transfusion-Dependent β-Thalassemia (TDT) and Severe Sickle Cell Disease (SCD) at …Business Wire (press release) bluebird bio (BLUE) Announces Early Data from Phase 3 Northstar-2 (HGB-207) Study of LentiGlobinTM Drug Product …StreetInsider.com |
Xconomy |
Bluebird Reports Early Results From Upgraded Gene Therapy
Xconomy One of the year’s most closely watched clinical studies could lead to a landmark approval of a gene therapy and throw wide open the debate over how to pay for expensive drugs. The first drips of data have emerged. Bluebird Bio (NASDAQ: BLUE) says the … Bluebird Bio’s gene therapy for blood disorders yields some …STAT Early Data for bluebird bio Gene–Therapy Candidate Show Some PromiseGenetic Engineering & Biotechnology News Bluebird Bio rebuilds case for blood disorder gene therapyFierceBiotech Endpoints News –Business Wire (press release) all 10 news articles » |
Medgadget (blog) |
Global Stem Cell Cartilage Regeneration Market 2017: Genzyme, CellGenix, EMD Serono and Sanofi Aventis
Medgadget (blog) A market study based on the ” Stem Cell Cartilage Regeneration ” across the globe, recently added to the repository of Market Research, is titled ‘Global Stem Cell Cartilage Regeneration Market 2017′. The Research report by QY Research Group is a … |
Nature.com |
Macrophages steal the show
Nature.com The past decade has seen remarkable advances in tumour immunology due to extensive research on inhibition of programmed cell death protein 1 (PD1) — which is expressed on T cells — and its ligand PDL1, which is expressed on tumour cells. However … |